← Back to Search

Checkpoint Inhibitor

Aspirin for Melanoma

Phase 2
Waitlist Available
Led By Adil Daud, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial is testing a combination of drugs to treat melanoma. The drugs may help to stop the growth of tumor cells.

Eligible Conditions
  • Melanoma
  • Cutaneous Melanoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate (ORR)
Secondary outcome measures
Median Duration of PFS
Median Overall Survival (OS)
Number of Participants With Reported Treatment-related Adverse Events
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (pembrolizumab, ipilimumab, aspirin)Experimental Treatment4 Interventions
Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aspirin
2014
Completed Phase 4
~55580
Ipilimumab
2014
Completed Phase 3
~2670
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,499 Previous Clinical Trials
11,936,461 Total Patients Enrolled
11 Trials studying Melanoma
366 Patients Enrolled for Melanoma
Merck Sharp & Dohme LLCIndustry Sponsor
3,884 Previous Clinical Trials
5,054,359 Total Patients Enrolled
120 Trials studying Melanoma
21,655 Patients Enrolled for Melanoma
Adil Daud, MDPrincipal InvestigatorUniversity of California, San Francisco
6 Previous Clinical Trials
277 Total Patients Enrolled
5 Trials studying Melanoma
195 Patients Enrolled for Melanoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
2018. "Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03396952.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top